Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

August 19, 2019

Phase 1 Trial Enrolling Advanced, Castration-resistent Patients to Test Triple Immunotherapy Combo

News

A Phase 1 trial is enrolling people with metastatic castration-resistant prostate cancer (mCRPC) to test Inovio Pharmaceutical‘s immunotherapy INO-5151 in combination with two other immunotherapies — Celldex’s CDX-301 and Bristol-Myers Squibb’s Opdivo ... Read more

August 8, 2019

First Patients Dosed in Phase 2b Trial Testing Oral Docetaxel Treatment for Advanced Prostate Cancer

News

A Phase 2b clinical trial evaluating ModraDoc006/r, Modra Pharmaceutical’s investigational oral treatment for metastatic castration-resistant prostate cancer, has started dosing patients, the company announced. ModraDoc006/r is a tablet formulation of ... Read more

July 31, 2019July 31, 2019

Invitae Offers Free Genetic Testing, Counseling for Hereditary Prostate Cancer

News

Invitae has launched a free genetic testing program to help connect prostate cancer patients to earlier diagnosis and treatments. The program also offers eligible patients free genetic counseling to ... Read more

July 3, 2019

Adding Xtandi to Xofigo Does Not Raise Risk of Bone Issues in CRPC, Study Says

News

Metastatic castration-resistant prostate cancer (CRPC) patients who receive Xtandi (enzalutamide) plus Xofigo (radium-223) in a real-world setting do not experience more fractures or bone-related events than those given Xofigo ... Read more

July 1, 2019

Phase 3 Trial of Topsalysin, Potential Treatment for Localized Prostate Cancer, Planned for Europe

News

The European Medicines Agency (EMA) has approved Sophiris Bio’s design for a Phase 3 trial to evaluate the potential of topsalysin (PRX302), an investigative agent for localized prostate cancer. ... Read more

June 13, 2019June 13, 2019

Study Shows How Prostate Cancer Cells Mimic Bone When They Metastasize

News

Prostate cancer cells can activate genes associated with bone formation and mimic bone cells’ behavior, allowing them to spread into bones. Those findings by by Duke University researchers, have ... Read more

June 3, 2019

American and Russian Scientists Team Up in Search for Potential Biomarker for Metastatic Prostate Cancer

News

Funded by a $380,000 grant from the National Cancer Institute, researchers at the University at Buffalo (UB) in New York and Moscow State University in Russia are collaborating to ... Read more

May 22, 2019May 22, 2019

Xtandi Extends Time to Disease Worsening in Certain Metastatic Prostate Cancer Patients – Without Added Side Effects – Study Shows

News

Xtandi (enzalutamide), an androgen receptor inhibitor, significantly delays disease progression — as assessed through radiological imaging — or death in metastatic hormone-sensitive prostate cancer (mHSPC) patients, a Phase 3 clinical trial ... Read more

May 6, 2019

Janssen Seeks Expanded FDA Approval of Erleada to Treat Metastatic Castration-sensitive Prostate Cancer

News

Janssen has submitted an application with the U.S. Food and Drug Administration (FDA) seeking the approval of its androgen receptor inhibitor Erleada (apalutamide) for patients with metastatic castration-sensitive prostate cancer ... Read more

May 2, 2019

Essa Pharma’s Androgen Receptor Inhibitor, EPI-7386, Selected as Lead Candidate Therapy

News

EPI-7386, a new androgen receptor inhibitor, was selected as Essa Pharma‘s lead candidate therapy for metastatic castration-resistant prostate cancer (mCRPC), the company announced. The company’s decision was supported by ... Read more

Pin It on Pinterest